Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 9, 2015, Pages 550-555

  Aref, Salah ^a   Kamel Areida, El Sayed ^b   Abdel Aaal, Mohamed Fathy ^b   Adam, Ola Mohamed ^b   El Ghonemy, Mohamed Sabry ^a   El Baiomy, Mohamed Ali ^a   Zeid, Tarek Abou ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b Mansoura University   (Egypt)

Author keywords

AML; IDH; Mutation; Prognosis

Indexed keywords

CYTARABINE; DAUNORUBICIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; NUCLEOPHOSMIN; PROTEIN TYROSINE KINASE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; NUCLEAR PROTEIN; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CYTOGENETICS; EGYPTIAN; EXON; FEMALE; GENE AMPLIFICATION; GENE DUPLICATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HEMOGLOBIN DETERMINATION; HUMAN; KARYOTYPING; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; RACE DIFFERENCE; THROMBOCYTE COUNT; ADOLESCENT; GENETICS; GENOTYPE; MIDDLE AGED; MUTATION; PATHOLOGY; PREVALENCE; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; FEMALE; GENOTYPE; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PREVALENCE; PROGNOSIS; YOUNG ADULT;

EID: 84939536435     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2015.05.009     Document Type: Article

References (15)

1. J. Byrd, K. Mrozek, R. Dodge, and et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) Blood 100 2002 4325 4336
2. F. Appelbaum, H. Gundacker, D. Head, and et al. Age and acute myeloid leukemia Blood 107 2006 3481 3485
3. J. Foran New prognostic markers in acute myeloid leukemia: perspective from the clinic Hematology 1 2010 47 55
4. J. Nomdedéu, M. Hoyos, M. Carricondo, and et al. Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group Leuk Res 36 2012 990 997
5. P. Paschka, R. Schlenk, V. Gaidzik, and et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication J Clin Oncol 28 2010 3636 3643
6. T. Sjöblom, S. Jones, L.D. Wood, and et al. The consensus coding sequences of human breast and colorectal cancers Science 314 2006 268 274
7. R. Cairns, and T. Mak Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities Cancer Discov 3 2013 730 741
8. A. Green, and P. Beer Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms N Engl J Med 362 2010 369 370
9. S. Yamaguchi, E. Iwanaga, K. Tokunaga, and et al. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation Eur J Haematol 92 2015 471 477
10. A. Tefferi, T. Lasho, O. Abdel-Wahab, and et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis Leukemia 24 2010 1302 1309
11. S. Chotirat, W. Thongnoppakhun, O. Promsuwicha, C. Boonthimat, and C. Auewarakul Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients J Hematol Oncol 5 2012 5
12. K.P. Patel, F. Ravandi, D. Ma, and et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features Am J Clin Pathol 135 2011 35 45
13. H. Yang, D. Ye, K. Guan, and Y. Xiong IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives Clin Cancer Res 18 2012 5562 5571
14. H. Yan, D. Parsons, G. Jin, and et al. IDH1 and IDH2 mutations in gliomas N Engl J Med 360 2009 765 773
15. D. Parsons, S. Jones, X. Zhang, and et al. An integrated genomic analysis of human glioblastoma multiforme Science 321 2008 1807 1812